In a recent clinical trial of EZN-2968, the antisense oligonucleotide inhibitor of HIF-1α successfully down-regulated both mRNA and protein levels of HIF-1α but failed to reduce the expression of VEGFA in tumor biopsies [18]. The gene discussed is HIF1A; the disease is neoplasm.